Archives of Clinical Infectious Diseases

Published by: Kowsar

Antibiotic and Mental Status Change

Masoud Mardani 1 , *
Author Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: January 2017, 12 (1); e45895
  • Published Online: January 22, 2017
  • Article Type: Editorial
  • Received: January 22, 2017
  • Accepted: January 22, 2017
  • DOI: 10.5812/archcid.45895

To Cite: Mardani M. Antibiotic and Mental Status Change, Arch Clin Infect Dis. 2017 ; 12(1):e45895. doi: 10.5812/archcid.45895.

Copyright © 2017, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Stip E, Darby RR, Bhattacharyya S, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016; 87(11): 1188-9[DOI][PubMed]
  • 2. Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014; 36(11): 1489-1511 e4[DOI][PubMed]
  • 3. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013; 17(6): 264[DOI][PubMed]
  • 4. Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections.
  • 5. Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000; 45(1): 5-7[DOI][PubMed]
  • 6. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23(3): 369-73[DOI][PubMed]
  • 7. Rothstein E, Clancy DD. Toxicity of disulfiram combined with metronidazole. N Engl J Med. 1969; 280(18): 1006-7[DOI][PubMed]
  • 8. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4): 433-42[DOI][PubMed]
  • 9. L'Huillier AG, Ing Lorenzini K, Crisinel PA, Rebsamen MC, Fluss J, Korff CM, et al. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics. 2011; 12(10): 1493-501[DOI][PubMed]
  • 10. Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2017; 135(2): 148-60[DOI][PubMed]
  • 11. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill. 2009; 14(30): 19287[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments